Is PUMA BIOTECHNOLOGY, INC. (PBYI) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 24.1% / 30% | 32.8% / 30% | 10.4% / 30% | 2.05% / 5% | ✗ NOT HALAL |
| DJIM | 24.1% / 33% | 32.8% / 33% | 10.4% / 33% | 2.05% / 5% | ✓ HALAL |
| MSCI | 34.7% / 33% | 47.3% / 33% | 15.0% / 33% | 2.05% / 5% | ✗ NOT HALAL |
| S&P | 24.1% / 33% | 32.8% / 33% | 10.4% / 33% | 2.05% / 5% | ✓ HALAL |
| FTSE | 34.7% / 33% | 47.3% / 33% | 15.0% / 50% | 2.05% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 74.5% | |
| Operating Margin | 22.7% | |
| Net Margin | 13.6% | |
| Return on Equity (ROE) | 28.0% | |
| Return on Assets (ROA) | 10.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $42M |
| Free Cash Flow | $42M |
| Total Debt | $29M |
| Debt-to-Equity | 21.9 |
| Current Ratio | 2.0 |
| Total Assets | $216M |
Price & Trading
| Last Close | $6.27 |
| 50-Day MA | $6.52 |
| 200-Day MA | $5.18 |
| Avg Volume | 425K |
| Beta | 1.3 |
|
52-Week Range
$2.58
| |
About PUMA BIOTECHNOLOGY, INC. (PBYI)
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. It sells its products through specialty pharmacy and distributor networks. The company has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is PUMA BIOTECHNOLOGY, INC. (PBYI) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), PUMA BIOTECHNOLOGY, INC. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is PUMA BIOTECHNOLOGY, INC.'s debt ratio?
PUMA BIOTECHNOLOGY, INC.'s debt ratio is 24.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 34.7%.
What are PUMA BIOTECHNOLOGY, INC.'s key financial metrics?
PUMA BIOTECHNOLOGY, INC. has a market capitalization of $309M, trailing P/E ratio of 10.0, and revenue of $228M. The company maintains a gross margin of 74.5% and a net margin of 13.6%. Return on equity stands at 28.0%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.